Caplin Point Laboratories opened at ₹2,419.80, in line with its previous close of ₹2,419.80. During today's session, the stock has traded between ₹2,325.20 and ₹2,425.60, with an average traded price of ₹2,358.79. It is currently showing a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Caplin Point Laboratories is now worth
₹ 25,635.00
giving a profit of
₹ 15,635.00 (156.35%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-58.20 (-2.41%)
Day High
₹2,425.60
Day Low
₹2,325.20
Day Open
₹2,419.80
Prev Close
₹2,419.80
Volume
1,67,353
Value Traded
₹39.48 Cr
1W Return
-9.31%
1M Return
-14.28%
3M Return
-8.59%
6M Return
38.23%
1Y Return
14.82%
Market Cap (₹ Cr.)
17,951
PE Ratio
27.10
PB Ratio
5.46
Dividend Yield
0.33%
ROE
17.89%
ROCE
21.96%
Book Value (₹)
443.33
Face Value (₹)
2.00
EPS (TTM)
23.27
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-9.31%
6 Week
-
1 Month
-14.28%
3 Month
-8.59%
9 Month
30.95%
Caplin Point Labs discloses voting results for 35th AGM resolutions
All six resolutions at Caplin Point Labs' 35th AGM passed with requisite majority. Appointment of Mr. D. Muralidharan as WTD saw highest dissent at 3.22%. Public institutional investors voted against WTD appointment at 38.13%. Financial statements and dividend declarations received 100% assent.
18 days agoCaplin Point Labs schedules AGM with ₹8 per share dividend payout
Caplin Point Laboratories schedules 35th AGM for September 25, 2026. Total FY26 dividend payout stands at ₹8 per share. Board seeks approval for re-appointment of MD and appointment of WTD. E-voting opens on September 22, 2026, and closes on September 24, 2026.
1mo agoCaplin Point Laboratories files FY26 BRSR report with stock exchanges
Caplin Point Laboratories files FY26 BRSR report covering domestic units and subsidiaries. Workforce totals 2,877 employees with 39% female representation. Total energy consumption falls 1.4% YoY to 1,97,534.46 GJ. Scope 1 and Scope 2 emissions recorded at 3,524.56 and 13,875.64 tCO2e respectively. Limited assurance provided by M/s Alagar & Associates LLP on core indicators.
1mo agoCaplin Steriles receives USFDA Form 483 with 10 observations
Caplin Steriles, a subsidiary of Caplin Point Laboratories, received a USFDA Form 483. The document lists 10 observations identified during a recent facility inspection. The company must submit a written response with corrective actions to the regulator.
1mo agoCaplin Point appoints Muralidharan as WTD, re-appoints Ganesan as MD
Caplin Point Laboratories Limited appointed D. Muralidharan as Whole-Time Director and re-appointed Dr. Sridhar Ganesan as Managing Director on August 12, 2026. The terms run for two years, starting August 12 and August 25, 2026, respectively. Both appointments require shareholder approval at the ensuing AGM. Muralidharan continues as CFO.
2mo agoCaplin Point Laboratories fixes Sept 18 record date for 35th AGM
Caplin Point Laboratories has set September 18, 2026, as the record date for its 35th AGM, scheduled for September 25, 2026. This date determines eligibility for voting rights and the final dividend for FY25-26, if declared.
2mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 5 years ago in Caplin Point Laboratories is now worth
₹ 25,635.00
giving a profit of
₹ 15,635.00 (156.35%)
Note: Past profits do not guarantee future returns.
